
Insulet Revenues Surge 30.7% as Omnipod 5 Reaches 600,000 Users
Insulet CorporationDescription
What this story covers
Insulet Corporation’s 2025 10-K reveals a transformative year with 30.7% revenue growth and 71.6% gross margins. Driven by the Omnipod 5’s expansion into Type 2 diabetes and international markets, the company now serves over 600,000 active users globally.
Story snapshot
CompanyInsulet Corporation
TickerPODD
VariantStandard detailed
Duration13:34
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001145197-26-000028
Sources1
Full Story Script
Content not available for this story.